scholarly journals Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (5) ◽  
pp. 8738-8751 ◽  
Author(s):  
Yusuke Inoue ◽  
Katsuhiro Yoshimura ◽  
Nobuya Kurabe ◽  
Tomoaki Kahyo ◽  
Akikazu Kawase ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adenosine Receptor ◽  
Small Cell ◽  
Receptor Expression ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
A2a Adenosine Receptor

scholarly journals P1.05-020 Opposing Prognostic Roles of CD73 and A2A Adenosine Receptor in Non-Small-Cell Lung Cancer

2017 ◽  
Vol 12 (1) ◽  
pp. S625-S626
Author(s):  
Yusuke Inoue ◽  
Katsuhiro Yoshimura ◽  
Nobuya Kurabe ◽  
Tomoaki Kahyo ◽  
Akikazu Kawase ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adenosine Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
A2a Adenosine Receptor

The Prognostic Impact of Pericardial Fat Volumes in Resected Non-small Cell Lung Cancer

2019 ◽  
Vol 27 (2) ◽  
pp. 481-489 ◽  
Author(s):  
Shuichi Shinohara ◽  
Ryo Otsuki ◽  
Kenichi Kobayashi ◽  
Masaki Matsuo ◽  
Ken Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Pericardial Fat

scholarly journals Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer

2020 ◽  
Vol 109 (3) ◽  
pp. 914-920 ◽  
Author(s):  
Shinkichi Takamori ◽  
Tetsuzo Tagawa ◽  
Gouji Toyokawa ◽  
Mototsugu Shimokawa ◽  
Fumihiko Kinoshita ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung

The prognostic impact of combined pulmonary fibrosis and emphysema in patients with clinical stage IA non-small cell lung cancer

Surgery Today ◽  
2017 ◽  
Vol 48 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Tomoyoshi Takenaka ◽  
Kiyomi Furuya ◽  
Koji Yamazaki ◽  
Naoko Miura ◽  
Kana Tsutsui ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Fibrosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Clinical Stage Ia ◽  
Stage Ia

scholarly journals Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer

Oncotarget ◽  
2014 ◽  
Vol 5 (22) ◽  
pp. 11054-11063 ◽  
Author(s):  
Emilio Bria ◽  
Francesca Di Modugno ◽  
Isabella Sperduti ◽  
Pierluigi Iapicca ◽  
Paolo Visca ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Alternative Splicing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Node Negative ◽  
Resected Node

scholarly journals OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii15-iii16
Author(s):  
Raees Tonse ◽  
Muni Rubens ◽  
Haley Appel ◽  
Martin C Tom ◽  
Matthew D Hall ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Brain Metastasis ◽  
Tumor Cell ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Small Cell ◽  
Receptor Expression ◽  
Small Cell Lung

Abstract Background Novel immunotherapeutic strategies, such as those targeting the PD-1/PD-L1 axis, are promising in patients with metastatic lung cancer and are often administered when tumors show PD-L1 positivity. The objective of this study was to analyze PD-L1 receptor discordance in tumor cell between the primary tumor and lung cancer brain metastasis (LCBM). Methods A systematic review of series published prior to April 2021 obtained from the Medline database of biopsied or resected LCBM evaluating PD-L1 discordance was performed using PRISMA guidelines. Weighted random effects models were used to calculate pooled estimates. Results Six full-text articles (n=247 patients) with a median of 32 patients in each study (range: 24–73 patients) reported PD-L1 receptor expression analyses of both primary lung tumors and brain metastases. The majority of patients (81%) were smokers, with 67% non-small cell lung cancer and 33% small cell lung cancer. The pooled estimate for overall PD-LI receptor concordance between primary and LCBM was 76% (95% CI: 52%-90). The positivity rate varied when analyzed by various cutoff levels of PD-L1 expression; for <1% expression, it was 41% (95% CI: 22%-62%) for primary vs. 58% (95% CI: 35%-78%) for LCBM; for PD-L1 expression of 1–50%, it was 24% (95% CI: 13%-40%) vs. 19% (95% CI: 10%-33%); and for PD-L1 >50% it was 12% (95% CI: 4%-33%) vs. 21% (95% CI: 14%-29%) (p=0.425). The pooled estimate for overall PD-LI receptor discordance between primary and LCBM was 17% (95% CI: 10%-27%). Meta-regression analysis showed that age, sex, smoking status, and histology were not associated with PD-LI receptor discordance. Conclusions PD-L1 status discordance in tumor cell occurs in approximately 20% of LCBM, with the greatest discordance in the <1% expression category. Awareness of this discordance is important for the selection of immune checkpoint inhibitor therapy as well as in the analysis of patterns of failures.

Sign in / Sign up

Export Citation Format

Share Document